Orlynvah™ (sulopenem etzadroxil/probenecid) – New drug approval
October 25, 2024 - Iterum Therapeutics announced the FDA approval of Orlynvah (sulopenem etzadroxil/probenecid), for the treatment of uncomplicated urinary tract infections (uUTI) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options.
Top